Anti‑proliferative action of IL‑6r-targeted antibody tocilizumab for non-small cell lung cancer cells

Oncology Letters

Volumn 9, Issue 5, 2015, Pages 2283-2288

  Kim, Na‑Hyun ^a   Kim, Seong‑Kwan ^a   Kim, Dong‑Soon ^a   Zhang, Dan ^a   Park, Jin‑A ^a   Yi, Hee ^a   Kim, Jin‑Suk ^a   Shin, Ho‑Chul ^a  

^a Konkuk University   (South Korea)

Author keywords

Anti proliferation; Interleukin 6 signaling; Nf b; Non small cell lung cancer; Tocilizumab

Indexed keywords

FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STAT3 PROTEIN; TOCILIZUMAB;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

EID: 84925397958     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3019     Document Type: Article

References (28)

1. Lam WK and Watkins DN: Lung cancer: future directions. Respirology 12: 471‑477, 2007.
2. Kishimoto T, Akira S, Narazaki M and Taga T: Interleukin‑6 family of cytokines and gp130. Blood 86: 1243‑1254, 1995.
3. Hodge DR, Hurt EM and Farrar WL: The role of IL‑6 and STAT3 in inflammation and cancer. Eur J Cancer 41: 2502‑2512, 2005.
4. Michalaki V, Syrigos K, Charles P and Waxman J: Serum levels of IL‑6 and TNF‑alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90: 2312‑2316, 2004.
5. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL and Gastl GA: Interleukin‑6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 73: 1882‑1888, 1994.
6. Zhang GJ and Adachi I: Serum interleukin‑6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 19: 1427‑1432, 1999.
7. Chung YC and Chang YF: Serum interleukin‑6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83: 222‑226, 2003.
8. Ohsugi Y and Kishimoto T: The recombinant humanized anti‑IL‑6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 8: 669‑681, 2008.
9. Bongartz T: Tocilizumab for rheumatoid and juvenile idiopathic arthritis. Lancet 371: 961‑963, 2008.
10. Kudo M, Jono H, Shinriki S, Yano S, Nakamura H, Makino K, Hide T, Muta D, Ueda M, Ota K, et al: Antitumor effect of humanized anti‑interleukin‑6 receptor antibody (tocilizumab) on glioma cell proliferation. Laboratory investigation. J Neurosurg 111:219‑225, 2009.
11. Haura EB, Livingston S and Coppola D: Autocrine interleukin‑6/interleukin‑6 receptor stimulation in non‑small‑cell lung cancer. Clin Lung Cancer 7: 273‑275, 2006.
12. Yi H, Cho HJ, Cho SM, Jo K, Park JA, Kim NH, Amidon GL, Kim JS and Shin HC: Blockade of interleukin‑6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int J Oncol 41: 310‑316, 2012.
13. Koyama Y, Mitsui N, Suzuki N, Yanagisawa M, Sanuki R, Isokawa K, Shimizu N and Maeno M: Effect of compressive force on the expression of inflammatory cytokines and their receptors in osteoblastic Saos‑2 cells. Arch Oral Biol 53: 488‑496, 2008.
14. Jiang XP, Yang DC, Elliott RL and Head JF: Down‑regulation of expression of interleukin‑6 and its receptor results in growth inhibition of MCF‑7 breast cancer cells. Anticancer Res 31: 2899‑2906, 2011.
15. Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M and Yao Y: Targeting interleukin‑6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 141: 125‑139, 2014.
16. Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M and Hudes GR: Randomised phase II study of siltuximab (CNTO 328), an anti‑IL‑6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/ prednisone alone in metastatic castration‑resistant prostate cancer. Eur J Cancer 48: 85‑93, 2012.
17. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, et al: Blockade of interleukin‑6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 152: 579‑592, 2011.
18. Hsu CP, Chen YL, Huang CC, Chou CC, Liu CL, Hung CH, Kao TY and Chung YC: Anti‑interleukin‑6 receptor antibody inhibits the progression in human colon carcinoma cells. Eur J Clin Invest 41: 277‑284, 2011.
19. Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B and Lahm H: Interleukin‑6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett 151: 31‑38, 2000.
20. Yilmaz S and Simsek I: Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab. Ther Clin Risk Manag 9: 403‑408, 2013.
21. Oldfield V, Dhillon S and Plosker GL: Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 69: 609‑632, 2009.
22. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, Merlin M, Clement C Morel‑Fournier B,et al: Murine anti‑interleukin‑6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78: 1198‑1204, 1991.
23. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T and Bendig MM: Reshaping a human antibody to inhibit the interleukin 6‑dependent tumor cell growth. Cancer Res 53: 851‑856, 1993.
24. Stärkel P, Charette N, Borbath I, Schneider-Merck, T, De Saeger C, Abarca J, Leclercq I and Horsmans Y: Ras inhibition in hepatocarcinoma by S‑trans‑trans‑farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events and angiogenesis. Mol Carcinog 51: 816‑825, 2012.
25. Sorriento D, Illario M, Finelli R and Iaccarino G: To NFκB or not to NFκB: The Dilemma on How to Inhibit a Cancer Cell Fate Regulator. Transl Med UniSa 4: 73‑85, 2012.
26. Chang TP and Vancurova I: NFκB function and regulation in cutaneous T‑cell lymphoma. Am J Cancer Res 3: 433‑445, 2013.
27. Martin AG: NFκB anti‑apoptotic or pro‑apoptotic, maybe both. Cell Cycle 9: 3131‑3132, 2010.
28. Viatour P, Merville MP, Bours V and Chariot A: Phosphorylation of NF‑kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci 30: 43‑52, 2005.